an investigational oral FGFR3 selective inhibitor, in hypochondroplasia (HCH). The results were presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference (Pharmachon 2024 ...

an investigational oral FGFR3 selective inhibitor, in hypochondroplasia (HCH). The results were presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference (Pharmachon 2024 ...

Achondroplasia is a genetic condition resulting from specific disruptions in the formation of endochondral bone. Telecanthus, exotropia, angle anomalies and cone–rod dystrophy have been observed as ...

A year earlier ImmunoGen revealed that the alliance had yielded three candidates, including one ADC directed at fibroblast growth factor receptor 3 (FGFR3) associated with bladder and brain ...